Platelet Activation and Mechanisms of Thromboembolism Formation in Patients with Severe COVID-19. Alternative Mechanisms of Hemostasis System Activity
- Авторлар: Kuznik B.1, Smolyakov Y.1, Tsybikov N.1, Shapovalov K.1
-
Мекемелер:
- Chita State Medical Academy
- Шығарылым: Том 143, № 4 (2023)
- Беттер: 335-358
- Бөлім: Articles
- URL: https://journals.rcsi.science/0042-1324/article/view/138959
- DOI: https://doi.org/10.31857/S0042132423040075
- EDN: https://elibrary.ru/ZBIHAN
- ID: 138959
Дәйексөз келтіру
Аннотация
The review highlights the mechanism of development of hypercoagulation and thrombosis in severe forms of COVID-19. The introduction of the SARS-CoV-2 virus into the host organism is carried out by the interaction of the spike protein S with the angiotensin-converting enzyme ACE-2, which is located in type 2 alveocytes, vascular endothelium, kidneys, liver and other organs. In the event of a serious condition in patients with COVID-19, both nonspecific and adaptive immunity are activated. Stimulation of the complement system with the appearance of C3a, C3b, C5a fragments and the membrane attack complex (MAC) creates conditions for the development of hypercoagulability. The involvement of the renin-angiotensin-aldosterone system in this process and the appearance of angiotensin 2 (Ang-2) further increase the intensity of hypercoagulability. When the SARS-CoV-2 virus enters cells, the protective reaction of the adaptive immune system can turn into a pathological one (a cytokine storm develops), characterized by a high level of pro-inflammatory cytokines IL-1α, IL-6, Il-8, TNF-α, IL-17, etc.) and chemokines (CCL-2, CCL-11, etc.), which ultimately leads to the development of thromboangiopathy or otherwise immunothrombosis in seriously ill patients with COVID-19. Patients with more severe lesions may develop a condition similar to DIC. At the same time, patients with COVID-19 have mild thrombocytopenia, elevated levels of fibrinogen, D-dimer, fibrinogen degradation products (FDP), which indicates intense thrombus formation, as well as short PT and APTT, due to a largely increased level of FVIII. In COVID-19, along with the classical one, an alternative pathway (bypassing thrombin) of regulation of the hemostasis system and thrombus formation appears, mainly associated with the influence of the spike protein S (PS, PROS1) of the SARS-CoV-2 virus and papain-like protease (PROS1). Protein S directly affects the conversion of fibrinogen to fibrin, as well as the activation of individual plasma coagulation factors. The alternative pathway of blood coagulation is also due to the activation of the complement system via the lectin pathway with the inclusion of metalloproteinases MASP-1, 2 and 3. In addition, the S protein activates tPA, which may be accompanied by hyperfibrinolysis. In seriously ill patients with COVID-19, platelets play an important role in the occurrence of thromboembolic complications. During the release reaction, platelets are released from the cytoplasm into the blood α and dense granules containing inflammatory cytokines and chemokines, which enhances the cytokine storm and, consequently, thrombus formation. By acting on the spike protein S, platelets enhance an alternative way of regulating the hemostasis system and thrombus formation.
Негізгі сөздер
Авторлар туралы
B. Kuznik
Chita State Medical Academy
Email: smolyakov@rambler.ru
Russia, Chita
Y. Smolyakov
Chita State Medical Academy
Хат алмасуға жауапты Автор.
Email: smolyakov@rambler.ru
Russia, Chita
N. Tsybikov
Chita State Medical Academy
Email: smolyakov@rambler.ru
Russia, Chita
K. Shapovalov
Chita State Medical Academy
Email: smolyakov@rambler.ru
Russia, Chita
Әдебиет тізімі
- Березовская Г.А., Петрищев Н.Н., Волкова Е.В. и др. Поражение сердечно-сосудистой системы при новой коронавирусной инфекции COVID-19 // Кардиология: новости, мнения, обучение. 2022. Т. 10 (4). С. 37–47. https://doi.org/10.33029/2309-1908-2022-10-4-37-47
- Кузник Б.И., Хавинсон В.Х. Влияние тималина на системы иммунитета, гемостаза и уровень цитокинов у пациентов с различными заболеваниями. Перспективы применения при COVID-19 // Врач. 2020. Т. 31 (7). С. 18–26. https://doi.org/10.29296/25877305-2020-07-03
- Кузник Б.И., Хавинсон В.Х., Линькова Н.С. COVID-19: влияние на иммунитет, систему гемостаза и возможные пути коррекции // Усп. физиол. наук. 2020. № 4. С. 51–63. https://doi.org/10.31857/S0301179820040037
- Кузник Б.И., Шаповалов К.Г., Смоляков Ю.Н. и др. Морфологический состав и показатели свертывающей системы крови у пациентов среднего и пожилого возраста с COVID-19 при лечении тоцилизумабом и тималином // Усп. геронтол. 2022. Т. 35 (3). С. 368–373. https://doi.org/10.34922/AE.2022.35.3.006
- Кузник Б.И., Ройтман Е.В., Цыбиков Н.Н. и др. Полипотентные механизмы регуляции системы гемостаза и тромбообразования при COVID-19 // Тромбоз, гемостаз, реология. 2023. № 2. (в печати)
- Хавинсон В.Х., Кузник Б.И. Осложнения у больных CОVID-19. Предполагаемые механизмы коррекции // Клин. мед. 2020. Т. 98 (4). С. 256–265.
- Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 // N. Engl. J. Med. 2020. V. 383 (2). P. 120–128. https://doi.org/10.1056/NEJMoa2015432
- Ahmad F., Kannan M., Ansari AW. Role of SARS-CoV-2-induced cytokines and growth factors in coagulopathy and thromboembolism // Cyt. Growth Factor Rev. 2022. V. 63. P. 58–68. https://doi.org/10.1016/j.cytogfr.2021.10.007
- Ahmed S., Zimba O., Gasparyan A.Y. Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad // Clin. Rheumatol. 2020. V. 39 (9). P. 2529–2543. https://doi.org/10.1007/s10067-020-05275-1
- Allaoui A., Khawaja A.A., Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection // Semin. Thromb. Hemost. 2021. V. 47 (4). P. 419–426. https://doi.org/10.1055/s-0041-1726033
- Al-Samkari H., Leaf R.S.K., Dzik W.H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection // Blood. 2020. V. 136 (4). P. 489–500. https://doi.org/10.1182/blood.2020006520
- Al-Tamimi A.O., Yusuf A.M., Jayakumar M.N. et al. SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19 // Int. J. Lab. Hematol. 2022. V. 44 (4). P. 712–721. https://doi.org/10.1111/ijlh.13829
- Arunachalam P.S., Wimmers F., Mok C.K.P. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans // Science. 2020. V. 369. P. 1210–1220. https://doi.org/10.1126/science.abc6261
- Barale C., Melchionda E., Morotti A., Russo I. Prothrombotic phenotype in COVID-19: focus on platelets // Int. J. Mol. Sci. 2021. V. 22 (24). P. 13638. https://doi.org/10.3390/ijms222413638
- Barnes B.J., Adrover J.M., Baxter-Stoltzfus A. et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps // J. Exp. Med. 2020. V. 217 (6). P. e20200652. https://doi.org/10.1084/jem.20200652
- Barrett T.J., Cornwell M., Myndzar K. et al. Platelets amplify endotheliopathy in COVID-19 // Sci. Adv. 2021. V. 7 (37). P. eabh2434. https://doi.org/10.1126/sciadv.abh2434
- Beura S.K., Panigrahi A.R., Yadav P., Singh S.K. Phytochemicals as potential therapeutics for SARS-CoV-2-induced cardiovascular complications: thrombosis and platelet perspective // Front. Pharmacol. 2021. V. 12. P. 658273. https://doi.org/10.3389/fphar.2021.658273
- Bumiller-Bini V., De Freitas Oliveira-Toré C., Carvalho T.M. et al. MASPs at the crossroad between the complement and the coagulation cascades – the case for COVID-19 // Genet. Mol. Biol. 2021. V. 44 (1). P. e20200199. https://doi.org/10.1590/1678-4685-GMB-2020-0199
- Bye A.P., Hoepel W., Mitchell J.L. et al. Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets // Blood. 2021. V. 138 (16). P. 1481–1489. https://doi.org/10.1182/blood.2021011871
- Canaday D.H. SARS-CoV-2 antibody responses to the ancestral SARS-CoV-2 strain and Omicron BA.1 and BA.4/BA.5 variants in nursing home residents after receipt of bivalent COVID-19 vaccine – Ohio and Rhode Island, September–November 2022 // MMWR. 2023. V. 72 (4). P. 100–106. https://doi.org/10.15585/mmwr.mm7204a4
- Candeloro M., Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis // Semin. Thromb. Hemost. 2023. V. 49 (1). P. 47–54. https://doi.org/10.1055/s-0042-1749661
- Chen J.M. Novel statistics predict the COVID-19 pandemic could terminate in 2022 // J. Med. Virol. 2022. V. 94 (6). P. 2845–2848. https://doi.org/10.1002/jmv.27661
- Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation // Blood. 2020. V. 135 (23). P. 2033–2040. https://doi.org/10.1182/blood.2020006000
- Conway E.M., Pryzdial E.L.G. Complement contributions to COVID-19 // Curr. Opin. Hematol. 2022. V. 29 (5). P. 259–265.
- Cugno M., Meroni P.L., Gualtierotti R. et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity // J. Autoimmun. 2021. V. 116. P. 102560. https://doi.org/10.1016/j.jaut.2020.102560
- D’Ardes D., Boccatonda A., Cocco G. et al. Impaired coagulation, liver dysfunction and COVID-19: discovering an intriguing relationship // World J. Gastroenterol. 2022. V. 28 (11). P. 1102–1112. https://doi.org/10.3748/wjg.v28.i11.1102
- Di Gennaro C., Galdiero M., Scherillo G. et al. Editorial COVID-19 and thrombosis 2023: new waves of SARS-CoV-2 infection, triage organization in emergency department and the association of VOCs/VOI with pulmonary embolism // Viruses. 2022. V. 14 (11). P. 2453. https://doi.org/10.3390/v14112453
- Diao B., Wang C.H., Wang R.S. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection // medRxiv. 2020. https://doi.org/10.1101/2020.03.04.20031120
- Escher R., Breakey N., Lämmle B. Severe COVID-19 infection associated with endothelial activation // Thromb. Res. 2020. V. 190. P. 62. https://doi.org/10.1016/j.thromres.2020.04.014
- Falcinelli E., Petito E., Gresele P. The role of platelets, neutrophils and endothelium in COVID-19 infection // Expert Rev. Hematol. 2022. V. 15 (8). P. 727–745. https://doi.org/10.1080/17474086.2022.2110061
- Fox S.E., Akmatbekov A., Harbert J.L. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans // Lancet Respir. Med. 2020. V. 8 (7). P. 681—686. https://doi.org/10.1016/S2213-2600(20)30243-5
- Frithiof R., Rostami E., Kumlien E. et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: a prospective study // Clin. Neurophysiol. 2021. V. 132 (7). P. 1733–1740. https://doi.org/10.1016/j.clinph.2021.03.016
- Fujimura Y., Holland L.Z. COVID-19 microthrombosis: unusually large vWF multimers are a platform for activation of the alternative complement pathway under cytokine storm // Int. J. Hematol. 2022. V. 115 (4). P. 457–469. https://doi.org/10.1007/s12185-022-03324-w
- Gao Y., Wang C., Kang K. et al. Cytokine storm may not be the chief culprit for the deterioration of COVID-19 // Viral. Immunol. 2021. V. 34 (5). P. 336–341. https://doi.org/10.1089/vim.2020.0243
- Gauchel N., Rieder M., Krauel K. et al. Complement system component dysregulation is a distinctive feature of COVID-19 disease // J. Thromb. Thrombolysis. 2022. V. 53 (4). P. 788–797. https://doi.org/10.1007/s11239-021-02617-x
- Ghasemzadeh M., Ahmadi J., Hosseini E. Platelet-leukocyte crosstalk in COVID-19: how might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis? // Thromb. Res. 2022. V. 213. P. 179–194. https://doi.org/10.1016/j.thromres.2022.03.022
- Gorog D.A., Storey R.F., Gurbel P.A. et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium // Nat. Rev. Cardiol. 2022. V. 19 (7). P. 475–495. https://doi.org/10.1038/s41569-021-00665-7
- Grobbelaar L.M., Venter C., Vlok M. et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19 // Biosci. Rep. 2021. V. 41 (8). P. BSR20210611. https://doi.org/10.1042/BSR20210611
- Grobler C., Maphumulo S.C., Grobbelaar L.M. et al. Covid-19: the rollercoaster of fibrin(ogen), D-dimer, von Willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes // Int. J. Mol. Sci. 2020. V. 21 (14). P. 5168. https://doi.org/10.3390/ijms21145168
- Gu S.X., Tyagi T., Jain K. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation // Nat. Rev. Cardiol. 2021. V. 18 (3). P. 194–209. https://doi.org/10.1038/s41569-020-00469-1
- Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. V. 382 (18). P. 1708–1720. https://doi.org/10.1056/NEJMoa2002032
- Han H., Yang L., Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection // Clin. Chem. Lab. Med. 2020. V. 58 (7). P. 1116–1120.
- Harrison C. Focus shifts to antibody cocktails for COVID-19 cytokine storm // Nat. Biotechnol. 2020. V. 38 (8). P. 905–908.
- Hoffmann M., Kleine-Weber H., Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells // Mol. Cell. 2020. V. 78. P. 779–784. https://doi.org/10.1016/j.molcel.2020.04.022
- Hottz E.D., Azevedo-Quintanilha I.G., Palhinha L. et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 // Blood. 2020. V. 136 (11). P. 1330–1341. https://doi.org/10.1182/blood.2020007252
- Iba T., Wada H., Levy J.H. Platelet activation and thrombosis in COVID-19 // Semin. Thromb. Hemost. 2023. V. 49 (1). P. 55–61. https://doi.org/10.1055/s-0042-1749441
- Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells // Nat. Rev. Mol. Cell Biol. 2022. V. 23 (1). P. 3–20. https://doi.org/10.1038/s41580-021-00418-x
- Jenny L., Dobó J., Gál P., Schroeder V. MASP-1 induced clotting – the first model of prothrombin activation by MASP-1 // PLoS One. 2015. V. 10 (12). P. e0144633. https://doi.org/10.1371/journal.pone.0144633
- Jenny L., Noser D., Larsen J.B. et al. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots // Mol. Immunol. 2019. V. 114. P. 1–9. https://doi.org/10.1016/j.molimm.2019.07.005
- Jiang S.Q., Huang Q.F., Xie W.M. et al. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants // Br. J. Haematol. 2020. V. 190 (1). P. e29–e33. https://doi.org/10.1111/bjh.16817
- Kakodkar P., Kaka N., Baig M.N. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19) // Cureus. 2020. V. 12 (4). P. e7560. https://doi.org/10.7759/cureus.7560
- Kaur S., Singh A., Kaur J. et al. Upregulation of cytokine signalling in platelets increases risk of thrombophilia in severe COVID-19 patients // Blood Cells Mol. Dis. 2022. V. 94. P. 102653. https://doi.org/10.1016/j.bcmd.2022.102653
- Kerch G. Severe COVID-19 A review of suggested mechanisms based on the role of extracellular matrix stiffness // Int. J. Mol. Sci. 2023. V. 24 (2). P. 1187. https://doi.org/10.3390/ijms24021187
- Koupenova M. Potential role of platelets in COVID-19: implications for thrombosis // Res. Pract. Thromb. Haemost. 2020. V. 4 (5). P. 737–740. https://doi.org/10.1002/rth2.12397
- Kozarcanin H., Lood C., Munthe-Fog L. et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation // J. Thromb. Haemost. 2016. V. 14 (3). P. 531–545. https://doi.org/10.1111/jth.13208
- Krarup A., Wallis R., Presanis J.S. et al. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2 // PLoS One. 2007. V. 2 (7). P. e623. https://doi.org/10.1371/journal.pone.0000623
- Kuhn C.C., Basnet N., Bodakuntla S. et al. Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein // bioRxiv. Preprint. 2022. https://doi.org/10.1101/2022.11.22.517574
- Lee M.H., Perl D.P., Steiner J. et al. Neurovascular injury with complement activation and inflammation in COVID-19 // Brain. 2022. V. 145 (7). P. 2555–2568. https://doi.org/10.1093/brain/awac151
- Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19 // Lancet Haematol. 2020. V. 7 (6). P. e438–e440.https://doi.org/10.1016/S2352-3026(20)30145-9
- Li T., Yang Y., Li Y. et al. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein // J. Clin. Invest. 2022. V. 132 (4). P. e150101. https://doi.org/10.1172/JCI150101
- Liang Y., Fang D., Gao X. et al. Circulating microRNAs as emerging regulators of COVID-19 // Theranostics. 2023. V. 13 (1). P. 125–147. https://doi.org/10.7150/thno.78164
- Liao M., Liu Y., Yuan J. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 // Nat. Med. 2020. V. 26 (6). P. 842–844. https://doi.org/10.1038/s41591-020-0901
- Lippi G., Favaloro E.J. What we know (and do not know) regarding th pathogenesis of pulmonary thrombosis in COVID-19 // Semin. Thromb. Hemost. 2023. V. 49 (1). P. 27–33. https://doi.org/10.1055/s-0041-1742091
- Liu Y., Sun W., Guo Y. et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study // Platelets. 2020. V. 31 (4). P. 490–496. https://doi.org/10.1080/09537104.2020.1754383
- Ma L., Sahu S.K., Cano M. et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection // Sci. Immunol. 2021. V. 6. P. eabh2259. https://doi.org/10.1126/sciimmunol.abh2259
- Magro C., Mulvey J.J., Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases // Transl. Res. 2020. V. 220. P. 1–13. https://doi.org/10.1016/j.trsl.2020.04.007
- McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications // Circ. Res. 2020. V. 127 (4). P. 571–587. https://doi.org/10.1161/CIRCRESAHA.120.317447
- Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages // Nat. Rev. Immunol. 2020. V. 20 (6). P. 355–362. https://doi.org/10.1038/s41577-020-0331-4
- Middleton E.A., He X.Y., Denorme F. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome // Blood. 2020. V. 136. P. 1169–1179. https://doi.org/10.1182/blood.2020007008
- Mizurini D.M., Hottz E.D., Bozza P.T., Monteiro R.Q. Fundamentals in COVID-19-associated thrombosis: molecular and cellular aspects // Front. Cardiovasc. Med. 2021. V. 8. P. 785738. https://doi.org/10.3389/fcvm.2021.785738
- Moraes E.C.D.S., Martins-Gonçalves R., Da Silva L.R. et al. Proteomic profile of procoagulant extracellular vesicles reflects complement system activation and platelet hyperreactivity of patients with severe COVID-19 // Front. Cell. Infect. Microbiol. 2022. V. 12. P. 926352. https://doi.org/10.3389/fcimb.2022.926352
- Morris G., Bortolasci C.C., Puri B.K. et al. The pathophysiology of SARS-CoV-2: a suggested model and therapeutic approach // Life Sci. 2020. V. 258. P. 118166. https://doi.org/10.1016/j.lfs.2020.118166
- Mukund K., Mathee K., Subramaniam S. Plasmin cascade mediates thrombotic events in SARS-CoV-2 infection via complement and platelet-activating systems // IEEE Open J. Eng. Med. Biol. 2020. V. 1. P. 220–227. https://doi.org/10.1109/OJEMB.2020.3014798
- Nahum J., Morichau-Beauchant T., Daviaud F. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) // JAMA Netw. Open. 2020. V. 3 (5). P. e2010478. https://doi.org/10.1001/jamanetworkopen.2020.10478
- Panigada M., Bottino N., Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis // J. Thromb. Haemost. 2020. V. 18 (7). P. 1738–1742. https://doi.org/10.1111/jth.14850
- Parums D.V. Editorial: the XBB.1.5. (“Kraken”) subvariant of Omicron SARS-CoV-2 and its rapid global spread // Med. Sci. Monit. 2023. V. 29. P. e939580. https://doi.org/10.12659/MSM.939580
- Passariello M., Vetrei C., Amato F., De Lorenzo C. Interactions of spike-RBD of SARS-CoV-2 and platelet factor 4: new insights in the etiopathogenesis of thrombosis // Int. J. Mol. Sci. 2021. V. 22 (16). P. 8562. https://doi.org/10.3390/ijms22168562
- Perico L., Morigi M., Galbusera M. et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation // Front. Immunol. 2022. V. 13. P. 827146. https://doi.org/10.3389/fimmu.2022.827146
- Poor H.D. Pulmonary thrombosis and thromboembolism in COVID-19 // Chest. 2021. V. 160 (4). P. 1471–1480. https://doi.org/10.1016/j.chest.2021.06.016
- Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses // Biochem. Biophys. Res. Commun. 2020. V. 526 (1). P. 135–140. https://doi.org/10.1016/j.bbrc.2020.03.044
- Rohlfing A.K., Rath D., Geisler T., Gawaz M. Platelets and COVID-19 // Hamostaseologie. 2021. V. 41 (5). P. 379–385. https://doi.org/10.1055/a-1581-4355
- Santos A.P., Couto C.F., Pereira S.S., Monteiro M.P. Is serotonin the missing link between COVID-19 course of severity in patients with diabetes and obesity? // Neuroendocrinology. 2022. V. 112. P. 1039–1045. https://doi.org/10.1159/000522115
- Sastry S., Cuomo F., Muthusamy J. COVID-19 and thrombosis: the role of hemodynamics // Thromb. Res. 2022. V. 212. P. 51–57. https://doi.org/10.1016/j.thromres.2022.02.016
- Sheth A.R., Grewal U.S., Patel H.P. et al. Possible mechanisms responsible for acute coronary events in COVID-19 // Med. Hypotheses. 2020. V. 143. P. 110125. https://doi.org/10.1016/j.mehy.2020.110125
- Sonmez O., Sonmez M. Role of platelets in immune system and inflammation // Porto Biomed. J. 2017. V. 2 (6). P. 311–314. https://doi.org/10.1016/j.pbj.2017.05.005
- Stark K. Platelet-neutrophil crosstalk and netosis // HemaSphere. 2019. V. 3. P. 89–91. https://doi.org/10.1097/HS9.0000000000000231
- Suh Y.J., Hong H., Ohana M. et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis // Radiology. 2021. V. 298. P. E70–E80. https://doi.org/10.1148/radiol.2020203557
- Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia // J. Thromb. Haemost. 2020. V. 18. P. 844–847. https://doi.org/10.1111/jth.14768
- Taus F., Salvagno G., Canè S. et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia // Arterioscler. Thromb. Vasc. Biol. 2020. V. 40 (12). P. 2975–2989. https://doi.org/10.1161/ATVBAHA.120.315175
- Thachil J., Tang N., Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19 // J. Thromb. Haemost. 2020. V. 18 (5). P. 1023–1026. https://doi.org/10.1111/JTH.14860
- Thillai M., Patvardhan C., Swietlik E.M. et al. Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19 // Thorax. 2021. V. 76 (2). P. 182–184. https://doi.org/10.1136/thoraxjnl-2020-215395
- Thomas W., Varley J., Johnston A. et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom // Thromb. Res. 2020. V. 191. P. 76–77. https://doi.org/101016/j.thromres.2020.04.028
- Tiwari R., Mishra A.R., Mikaeloff F. et al. In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis // Comput. Struct. Biotechnol. J. 2020. V. 18. P. 3734–3744. https://doi.org/10.1016/j.csbj.2020.11.005
- Ulanowska M., Olas B. Modulation of hemostasis in COVID-19; blood platelets may be important pieces in the COVID-19 puzzle // Pathogens. 2021. V. 10 (3). P. 370. https://doi.org/10.3390/pathogens10030370
- Vadasz Z., Brenner B., Toubi E. Immune-mediated coagulopathy in COVID-19 infection // Semin. Thromb. Hemost. 2020. V. 46 (7). P. 838–840. https://doi.org/10.1055/s-0040-1714272
- Varatharajah N., Rajah S. Microthrombotic complications of COVID-19 are likely due to embolism of circulating endothelial derived ultralarge von Willebrand factor (eULvWF) decorated-platelet strings // Fed. Pract. 2020. V. 37 (6). P. 258–259.
- Violi F., Pignatelli P., Cammisotto V. et al. COVID-19 and thrombosis: clinical features, mechanism of disease, and therapeutic implications // Kardiol. Pol. 2021. V. 79 (11). P. 1197–1205. https://doi.org/10.33963/KP.a2021.154
- Wang J., Doran J. The many faces of cytokine release syndrome-related coagulopathy // Clin. Hematol. Int. 2021. V. 3 (1). P. 3–12. https://doi.org/10.2991/chi.k.210117.001
- Wienkamp A.K., Erpenbeck L., Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis // Front. Immunol. 2022. V. 13. P. 953129. https://doi.org/10.3389/fimmu.2022.953129
- Wool G.D., Miller J.L. The impact of COVID-19 disease on platelets and coagulation // Pathobiology. 2021. V. 88 (1). P. 15–27. https://doi.org/10.1159/000512007
- Xiang M., Wu X., Jing H. et al. The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors // Front. Immunol. 2022. V. 13. P. 955654. https://doi.org/10.3389/fimmu.2022.955654
- Xiao T., Lu J., Zhang J. et al. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent // Nat. Struct. Mol. Biol. 2021. V. 28. P. 202–209. https://doi.org/10.1038/s41594-020-00549-3
- Yang X., Yang Q., Wang Y. et al. Thrombocytopenia and its association with mortality in patients with COVID-19 // J. Thromb. Haemost. 2020. V. 18. P. 1469–1472. https://doi.org/10.1111/jth.14848
- Ye Q., Wang B., Mao J. The pathogenesis and treatment of the “cytokine storm” in COVID-19 // J. Infect. 2020. V. 80. P. 607–613. https://doi.org/10.1016/j.jinf.2020.03.037
- Yu J., Yuan X., Chen H. et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition // Blood. 2020. V. 136 (18). P. 2080–2089. https://doi.org/10.1182/blood.2020008248
- Zhang S., Liu Y., Wang X. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 // J. Hematol. Oncol. 2020. V. 13 (1). P. 120. https://doi.org/10.1186/s13045-020-00954-7
- Zhang Y., Zeng X., Jiao Y. et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19 // Thromb. Res. 2020. V. 193. P. 110–115.
- Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. V. 395. P. 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
- Zhu A., Real F., Capron C. et al. Infection of lung megakaryo-cytes and platelets by SARS-CoV-2 anticipate fatal COVID-19 // Cell. Mol. Life Sci. 2022. V. 79 (7). P. 365. https://doi.org/10.1007/s00018-022-04318-x
- Zuo Y., Yalavarthi S., Shi H. et al. Neutrophil extracellular traps in COVID-19 // JCI Insight. 2020. V. 5 (11). P. e138999. https://doi.org/10.1172/jci.insight.138999